<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEXTROAMPHETAMINE SULFATE</span><br/>(dex-troe-am-fet'a-meen)<br/><span class="topboxtradename">Dexampex, </span><span class="topboxtradename">Dexedrine, </span><span class="topboxtradename">Oxydess II <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Spancap No. 1<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">respiratory and cerebral stimulant</span>; <span class="classification">amphetamine</span>; <span class="classification">anorexiant</span><br/><b>Prototype: </b>Amphetamine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets; 5 mg, 10 mg, 15 mg sustained release capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Dextrorotatory isomer of amphetamine. Anorexigenic action is thought to result from CNS stimulation and possibly from loss
         of acuity of smell and taste.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>On a weight basis, has less pronounced effect on cardiovascular and peripheral nervous systems and is a more potent appetite
         suppressant than amphetamine. CNS stimulating effect approximately twice that of racemic amphetamine. In hyperkinetic children,
         amphetamines reduce motor restlessness by an unknown mechanism.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct in short-term treatment of exogenous obesity, narcolepsy, and attention deficit disorder with hyperactivity in children
         (also called minimal brain dysfunction or hyperkinetic syndrome).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Adjunct in epilepsy to control ataxia and drowsiness induced by barbiturates; to combat sedative effects of trimethadione
         in absence seizures.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sympathomimetic amines, glaucoma, agitated states, psychoses (especially in children), advanced arteriosclerosis,
         symptomatic heart disease, moderate to severe hypertension, hyperthyroidism, history of drug abuse, during or within 14 d
         of <small>MAO</small> inhibitor therapy, as anorexiant in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C). Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Narcolepsy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 520 mg 13 times/d at 46 h intervals<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>612 y</i>, 5 mg/d, may increase by 5 mg at weekly intervals; &gt;<i>12 y</i>, 10 mg/d, may increase by 10 mg at weekly intervals<br/><br/><span class="indicationtitle">Attention Deficit Disorder</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>35 y</i>, 2.5 mg 12 times/d, may increase by 2.5 mg at weekly intervals; <i><img src="../images/special/greaterorequal.gif"/>6 y</i>, 5 mg 12 times/d, may increase by 5 mg at weekly intervals (max: 40 mg/d)<br/><br/><span class="indicationtitle">Obesity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg 13 times/d or 1015 mg of sustained release once/d 3060 min a.c.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that sustained release capsule is not chewed or crushed. It <small>MUST</small> be swallowed whole.
         </li>
<li>Give 3060 min before meals for treatment of obesity. Give long-acting form in the morning.</li>
<li>Give last dose no later than 6 h before patient retires (1014 h before bedtime for sustained release form) to avoid
            insomnia.
         </li>
<li>Store in tightly closed containers at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Nervousness, <span class="speceff-common">restlessness,</span> hyperactivity, <span class="speceff-common">insomnia,</span> euphoria, dizziness, headache; <b> <i>with prolonged use</i> </b>severe depression, psychotic reactions. <span class="typehead">CV:</span> Palpitation, tachycardia, elevated BP. <span class="typehead">GI:</span> Dry mouth, unpleasant taste, anorexia, weight loss, diarrhea, constipation, abdominal pain. <span class="typehead">Other:</span> Impotence, changes in libido, unusual fatigue, increased intraocular pressure, marked dystonia of head, neck, and extremities;
      sweating. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Dextroamphetamine may cause significant elevations in <span class="alt">plasma corticosteroids</span> (evening levels are highest) and increases in <span class="alt">urinary epinephrine</span> excretion (during first 3 h after drug administration).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Acetazolamide,</b> <b>sodium bicarbonate</b> decrease dextroamphetamine elimination; <b>ammonium chloride,</b> <b>ascorbic acid</b> increase dextroamphetamine elimination; effects of both <span class="classification">barbiturates</span> and dextroamphetamine may be antagonized; <b>furazolidone</b> may increase BP effects of <span class="classification">amphetamines</span>interaction may persist for several weeks after discontinuing <b>furazolidone;</b> antagonizes antihypertensive effects of <b>guanethidine,</b> <b>guanadrel;</b> <span class="classification">mao inhibitors</span>, <b>selegiline</b> can causehypertensive crisis (fatalities reported)do not administer <span class="classification">amphetamines</span> during or within 14 d of these drugs; <span class="classification">phenothiazines</span> may inhibit mood elevating effects of <span class="classification">amphetamines</span>; <span class="classification">tricyclic antidepressants</span> enhance dextroamphetamine effects because of increased <b>norepinephrine</b> release; <span class="classification">beta-adrenergic agonists</span> increase cardiovascular adverse effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapid. <span class="typehead">Peak:</span> 15 h. <span class="typehead">Duration:</span> Up to 10 h. <span class="typehead">Distribution:</span> All tissues especially the CNS. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Renal elimination; excreted in breast milk. <span class="typehead">Half-Life:</span> 1030 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor growth rate closely in children.</li>
<li>Interrupt therapy or reduce dosage periodically to assess effectiveness in behavior disorders.</li>
<li> 								Note: Tolerance to anorexiant effects may develop after a few weeks, however, tolerance does not appear to develop when dextroamphetamine
            is used to treat narcolepsy. 							
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Swallow sustained release capsule whole with a liquid; do not chew or crush.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Taper drug gradually following long-term use to avoid extreme fatigue, mental depression, and prolonged sleep pattern.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>